MedTrace Logo

An Insulin Sensitivity Study in Healthy Subjects

NCT02922426 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-08-22

No results posted yet for this study

Summary

This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ALKS 3831

Daily dosing for 21 consecutive days

DRUG

Olanzapine

Daily dosing for 21 consecutive days

DRUG

Placebo

Daily dosing for 21 consecutive days

Sponsors & Collaborators

  • Alkermes, Inc.

    lead INDUSTRY

Principal Investigators

  • David McDonnell, MD · Alkermes, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-07-20
Completion
2017-07-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922426 on ClinicalTrials.gov